BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

Journal: Science Translational Medicine

Published: 2020-02-19

DOI: 10.1126/scitranslmed.aax2625

Affiliations: 17

Authors: 34

Go to article
Institutions Share
Department of Translational Research, Curie Institute, France 0.35
Developmental Biology, Cancer, Genetics and Epigenetics, Institut Curie, France 0.10
Laboratory of Tumor and Development Biology (LBTD), ULg, Belgium 0.09
Cancer GenomiCs.nl (CGC.nl), Netherlands 0.06
Department of Pathology, Institut Curie, France 0.06
Curie Institute, France 0.06
Biopôle, ENVA, France 0.04
Animal Physiopathology and Biotherapy of the Muscle and Nervous System (PANTHER), France 0.03
Bioinformatics and Computational Systems Biology of Cancer, France 0.03
Genetics and Biology of Cancers, France 0.03
Signalisation, Neurobiologie et Cancer, France 0.03
Queen's Cancer Research Institute (QCRI), Queen's University, Canada 0.03
NIH NCI Laboratory of Molecular Pharmacology (LMP), United States of America (USA) 0.03
Department of Medical Oncology, Curie Institute, France 0.02
Physiologie Animale et Systèmes d'Elevage (PHASE), INRAE, France 0.01
Department of Surgery, Curie Institute, France 0.01
Immunity and Cancer Unit, France 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER